ArticleThe Lancet. Oncology2023

Expression of concern-Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

The Editors Of The Lancet OncologyPubMed ↗Publisher ↗

No numbers read from the abstract.